Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LRK-4189 |
| Synonyms | |
| Therapy Description |
LRK-4189 targets PIP4K2C for degradation, which may lead to tumor cell death and activation of anti-tumor immune response (Journal for ImmunoTherapy of Cancer. 2025;13:1281). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LRK-4189 | LRK4189|LRK 4189 | LRK-4189 targets PIP4K2C for degradation, which may lead to tumor cell death and activation of anti-tumor immune response (Journal for ImmunoTherapy of Cancer. 2025;13:1281). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07498725 | Phase Ib/II | LRK-4189 Fluorouracil + Leucovorin + LRK-4189 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + LRK-4189 | A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors | Not yet recruiting | GBR | FRA | 0 |